Kyverna Reports Deep, Durable Phase 2 Data for Miv-cel in Myasthenia Gravis, Reinforcing Phase 3 Confidence

summarizeSummary

Kyverna Therapeutics announced exceptionally strong longer-term Phase 2 data for its miv-cel therapy in generalized myasthenia gravis, showing 100% patient response and durable, drug-free remission potential.

check_boxKey Events · Product Development and Regulatory · KYTX

• Positive Longer-Term Phase 2 Data

  Miv-cel demonstrated deep and durable clinical responses in 100% of generalized myasthenia gravis patients, with sustained benefits observed out to one year.

• Strong Efficacy and Safety Profile

  Patients achieved rapid and robust reductions in MG-ADL and QMG scores, with 57% reaching minimal symptom expression. The therapy was well-tolerated with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) events.

• Reinforces Phase 3 Confidence

  The data strengthens conviction in miv-cel's differentiated profile and the ongoing Phase 3 registrational trial, supporting its potential for durable, drug-free remission.

• Conference Call Scheduled

  The company will host a conference call on April 22, 2026, to discuss these results and updated data for stiff person syndrome.

auto_awesomeAnalysis · KYTX · Life Sciences

This 8-K announces highly positive longer-term Phase 2 data for Kyverna's lead CAR T-cell therapy, miv-cel, in generalized myasthenia gravis (gMG). The reported 100% patient response rate with rapid, sustained, and durable improvements in key clinical measures (MG-ADL, QMG) out to 52 weeks, coupled with a favorable safety profile and the ability to achieve drug-free remission, significantly de-risks the ongoing Phase 3 registrational trial. These results strengthen miv-cel's potential as a best-in-class treatment and are a major catalyst for the company's neuroimmunology franchise.